Skip to content
Medical Health Aged Care

Parkinson’s disease researchers develop cellular ‘invisibility cloak’ to protect neural grafts

The Florey 2 mins read

Cloaked human neural grafts evade immune detection

Florey researchers have engineered a way to fool the immune system into accepting neural grafts as part of the body, rather than attacking them as foreign objects.

The research, published today in Cell Stem Cell, could signal an end to the reliance on drugs necessary to prevent graft rejection, not just for Parkinson’s disease neural grafts, but for other cell transplants.

The study’s lead author, Florey Deputy Director Professor Clare Parish, Head of Stem Cells and Neural Development, said Parkinson’s disease is a neurodegenerative condition that affects an estimated 10 million people globally and 150,000 people in Australia.*

“Parkinson’s disease causes specific nerve cells – neurons – to die, leading to symptoms that include difficulties moving, tremor, stiffness, and impaired balance. Neural grafting is an emerging treatment to replace those dead neurons,” Professor Parish said.

“Human neural graft trials are underway overseas but, as with other types of organ or cell transplants, patients need to stop their body rejecting the graft by taking immunosuppressant drugs several times a day. Unfortunately, these drugs carry their own risks and side-effects.”

Professor Parish said the team, in collaboration with the University of Toronto, has taken neural grafts to the next generation, and the work could benefit other cell transplants.

"We’ve engineered neurons which are like those currently in clinical trials for Parkinson’s disease, but we’ve also given them an invisibility cloak. They can hide in plain sight from the immune system. This could mean an end to the need for anti-rejection drugs."

The paper’s co-lead author, Dr Chiara Pavan, who specialises in neuroimmunology, said the team tested the engineered neuronal grafts in mice with a ‘humanised’ immune system, and in rats modelling Parkinson’s disease.

“Current medications treat the symptoms of Parkinson’s disease, but these grafts target the cause by replacing dead neurons,” she said.

“After receiving their neuronal graft, the mice showed no negative effects – which is a good indication that the human immune system will accept the neurons. In rats, the symptoms of Parkinson’s disease were abolished, indicating the cloaked neurons don’t lose their effectiveness against the disease.”

Dr Pavan said the neurons also had an ‘off’ switch so that they can be activated if desired, to eliminate the risk of tumours developing from grafts.

Professor Parish said it is an exciting result and the technology has huge potential.

“We’ve made a cell product that in future could be implanted in people with Parkinson’s disease, reducing the need for anti-rejection drugs,” Professor Parish says.

"Stem cells can be turned into any kind of cell, and we’ve effectively made them invisible to the immune system.

“This is the next generation of neurological treatment, and it could be used as a safe, off-the-shelf cell product suitable for treating diseases for which cell-based therapies are a viable option, such as stroke, Huntington’s disease, heart diseases and diabetes.”

 


Contact details:
Kathryn Powley

Media and Communications Manager

P +61 456 666 271
E [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.